North America monoclonal antibodies market is projected to grow by 10.4% annually in the forecast period and reach $133.4 billion by 2030, driven by the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.
Highlighted with 24 tables and 48 figures, this 102-page report 鈥淣orth America Monoclonal Antibodies (mAbs) 麻豆原创 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire North America monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country.
Based on Source, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
鈥� Human
鈥� Humanized
鈥� Chimeric
鈥� Murine
Based on Category, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
鈥� Branded mAbs
鈥� Biosimilar mAbs
Based on Production Type, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
鈥� In Vitro Production
鈥� In Vivo Production
Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
鈥� Cancer
o Breast Cancer
o Colorectal Cancer
o Lung Cancer
o Ovarian Cancer
o Other Cancer Types
鈥� Autoimmune Diseases
鈥� Inflammatory Diseases
鈥� Infectious Diseases
鈥� Other Applications
By End User, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
鈥� Hospitals
鈥� Research Institutes
鈥� Other End Users
Geographically, the following national/local markets are fully investigated:
鈥� U.S.
鈥� Canada
鈥� Mexico
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of 麻豆原创 Research Methodology 11
1.2.2 麻豆原创 Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 麻豆原创 Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 麻豆原创 Overview and Dynamics 19
2.1 麻豆原创 Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the 麻豆原创 22
2.2 Major Growth Drivers 24
2.3 麻豆原创 Restraints and Challenges 29
2.4 Emerging Opportunities and 麻豆原创 Trends 32
2.5 Porter鈥檚 Fiver Forces Analysis 36
3 Segmentation of North America 麻豆原创 by Source 40
3.1 麻豆原创 Overview by Source 40
3.2 Human 42
3.3 Humanized 43
3.4 Chimeric 44
3.5 Murine 45
4 Segmentation of North America 麻豆原创 by Category 46
4.1 麻豆原创 Overview by Category 46
4.2 Branded mAbs 48
4.3 Biosimilar mAbs 49
5 Segmentation of North America 麻豆原创 by Production Type 50
5.1 麻豆原创 Overview by Production Type 50
5.2 In Vitro Production 52
5.3 In Vivo Production 53
6 Segmentation of North America 麻豆原创 by Application 54
6.1 麻豆原创 Overview by Application 54
6.2 Cancer 56
6.2.1 Breast Cancer 58
6.2.2 Colorectal Cancer 59
6.2.3 Lung Cancer 60
6.2.4 Ovarian Cancer 61
6.2.5 Other Cancer Types 62
6.3 Autoimmune Diseases 63
6.4 Inflammatory Diseases 64
6.5 Infectious Diseases 65
6.6 Other Applications 66
7 Segmentation of North America 麻豆原创 by End User 67
7.1 麻豆原创 Overview by End User 67
7.2 Hospitals 69
7.3 Research Institutes 70
7.4 Other End Users 71
8 North America 麻豆原创 2019-2030 by Country 72
8.1 Overview of North America 麻豆原创 72
8.2 U.S. 75
8.3 Canada 78
8.4 Mexico 80
9 Competitive Landscape 82
9.1 Overview of Key Vendors 82
9.2 New Product Launch, Partnership, Investment, and M&A 85
9.3 Company Profiles 86
Abbott Laboratories 86
AbbVie, Inc. 88
Amgen Inc. 89
AstraZeneca plc 90
Bayer AG 91
Bristol-Myers Squibb Company 92
Eli Lilly 93
F. Hoffmann-La Roche Ltd. 94
GlaxoSmithKline Plc 95
Johnson & Johnson 96
Merck & Co., Inc. 97
Mylan N.V 98
Norvatis AG 99
Pfizer 100
Sanofi S.A. 101
RELATED REPORTS 102
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
听
听
*If Applicable.
